Drug intelligence / Profile preview

kyotorphin

Development stage
Preclinical
Modality
Peptides
Administration
Intracerebroventricular, Intraperitoneal, Systemic
01

Overview

Kyotorphin is an endogenous opioid analgesic dipeptide (L-tyrosyl-L-arginine) first isolated from the bovine brain in 1979. It is primarily known for its antinociceptive properties, which it exerts not by direct binding to opioid receptors, but by stimulating the release of Met-enkephalin in the brain and spinal cord. Kyotorphin acts through a specific G protein-coupled receptor (the kyotorphin receptor) that mediates the activation of phospholipase C and inhibition of adenylyl cyclase via Gi proteins. Beyond its role in pain modulation, research has explored its potential as a neuroprotective agent in Alzheimer's disease models, an anti-inflammatory modulator, and a precursor for antimicrobial derivatives. It is unevenly distributed in the brain, with high concentrations in regions associated with the pain pathway, such as the cerebral cortex, midbrain, and medulla oblongata.

Other names
L-tyrosyl-L-arginineKTPL-Tyr-L-Argtyrosine-arginine
02

Targets

KTR (Kyotorphin receptor)

Beyond the preview

Go deeper on kyotorphin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on kyotorphin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call